If you are a sales professional or want to become one, or if you are looking for a new sales job, you will face one of the toughest interview processes of any job seeker.
Additional Analysis of 18 Month Data of the SORT OUT III Trial Provides Detail on Safety and Efficacy Outcomes in Patients With Diabetes, Acute Coronary Syndrome, or Treatment of Multiple Lesions STOCKHOLM, September 2, 2010 (HSMN NewsFeed) –Three ne…
Devices, Interventional Cardiology
Cordis, CYPHER, Sirolimus, Drug Eluting Stent, Zotarolimus, Medtronic
Posts under ‘Medical Sales Jobs’
Long Term Data Presented at ESC 2010 Further Support the Benefit of The CYPHER(R) Sirolimus Drug-Eluting Stent Compared to The ENDEAVOR(R) Zotarolimus-Eluting Stent in Important High-Risk Subgroups
Cardiogenesis Comments on the STAR-Heart Study Presented at European Society of Cardiology (ESC) 2010 Congress
IRVINE, Calif., Sept. 2 (HSMN NewsFeed) — Cardiogenesis Corporation (OTCQB: CGCP), released comments today regarding the STAR-heart study. The STAR-heart study, which was presented at the European Society of Cardiology 2010 Congress in August 2010, r…
Regenerative Medicine, Devices, Cardiology
Cardiogenesis, STAR-heart study, stem cell, heart failure, cardiomyopathy
VA Puget Sound Facilities Standardize with FlexiPort(R) Disposable Cuffs, Reinforcing a Commitment to Patient Safety
Welch Allyn blood pressure cuff technology helps fight infection and lower the cost of health care SKANEATELES FALLS, N.Y.–(Healthcare Sales & Marketing Network)–Welch Allyn, a big global manufacturer of frontline pharmaceutical products and solutions, h…
Devices
Welch Allyn, FlexiPort, blood pressure cuff, blood pressure
ConvaTec Expands AQUACEL(R) Dressing Product Line With Introduction of New Ribbon Dressing
More Convenient Size is Ideal for Certain Cavity Wounds SKILLMAN, N.J., Sept. 2 (HSMN NewsFeed) — ConvaTec, a world-leading developer and marketer of innovative laboratory technologies for community and hospital care, announced today the introduction …
Devices, Wound Care
ConvaTec, AQUACEL
GI Dynamics Announces Distribution Agreement with Elemental Healthcare for the EndoBarrier Gastrointestinal Liner
LEXINGTON, Mass. & HUNGERFORD, England–(Healthcare Sales & Marketing Network)–GI Dynamics, a leader in non-surgical, endoscopic treatments for type 2 diabetes and obesity, today announced it has entered into a new agreement with Elemental Healthcare, bas…
Devices, Distribution
GI Dynamics, Elemental Healthcare, EndoBarrier
Pfizer to Acquire FoldRx Pharmaceuticals
FoldRx Focused on First-in-Class, Disease-Modifying, Oral Therapeutics to Treat Diseases Caused by Protein Misfolding Lead Product Candidate, Tafamidis, in Registration in the European Union as First-in-Class Oral Therapy for Transthyretin Amyloid Polyn…
Biopharmaceuticals, Mergers & Acquisitions
Pfizer, FoldRx Pharmaceuticals
InfraReDx Receives FDA Clearance for LipiScan IVUS Coronary Imaging System
First Catheter to Combine Near-Infrared Spectroscopy with Intravascular Ultrasound A Worthwhile New Tool to Characterize Coronary Plaque and Improve Coronary Stenting BURLINGTON, Mass., Sept. 1 (HSMN NewsFeed) — InfraReDx, Inc., a medical device com…
Devices, Cardiology
InfraReDx, LipiScan, IVUS Coronary Imaging, intravascular ultrasound
Celator(R) Pharmaceuticals Raises $20 Million in Series D Financing
PRINCETON, N.J., Sept. 1 (HSMN NewsFeed) — Celator Pharmaceuticals, a privately held medical company developing new and more effective therapies to treat cancer based on the company’s proprietary technology, today announced that it raised $20 mil…
Biopharmaceuticals, Venture Capital
Celator Pharmaceuticals
Quidel Announces FDA Clearance of Its RapidVue(R) hCG Pregnancy Lateral Flow Diagnostic Test
SAN DIEGO–(Healthcare Sales & Marketing Network)–Quidel Corporation (NASDAQ: QDEL ), a big provider of rapid diagnostic testing solutions, announced today that it has received 510(k) clearance from the United States Food and Drug Administration (FDA)…
Diagnostics, FDA
Quidel, RapidVue, hCG, human Chorionic Gonadotropin, pregnancy test
Allergan, Inc. Receives FDA Approval for LUMIGAN(R) 0.01% as First-Line Therapy Indicated for the Reduction of Elevated Intraocular Pressure in Glaucoma Patients
IRVINE, Calif.–(Healthcare Revenue & Marketing Network)–Allergan, Inc. (NYSE:AGN ) today announced the United States Food and Drug Administration (FDA) has approved LUMIGAN® (bimatoprost ophthalmic solution) 0.01% as a first-line therapy indicated for …
Biopharmaceuticals, Ophthalmology, FDA
Allergan, LUMIGAN, bimatoprost, intraocular pressure, glaucoma
